蘭衞醫學(301060.SZ)2022年度扣非淨利潤預增240.72%-328.65%
格隆匯2月1日丨蘭衞醫學(301060.SZ)公佈,預計2022年度歸屬於上市公司股東的淨利潤6.1億元-7.5億元,同比增長199.25%-267.94%;扣除非經常性損益後的淨利潤6.2億元-7.8億元,同比增長240.72%-328.65%。
報吿期內,公司依託不斷迭代的“產品+服務”的商業模式加強市場拓展,積極發揮公司區域中心服務體系及市場渠道的優勢,持續推廣先進醫學檢驗技術的臨牀應用,在開展體傳統體外診斷產品貿易的基礎上開闢平台業務,以滿足各級醫療機構的差異化需求。
報吿期內,公司體外診斷產品銷售業務收入較同期平穩發展,醫學檢驗及病理診斷服務整體收入有較大增幅。其中,公司響應國家政策號召,積極參與各地新冠疫情聯防聯控工作,踐行企業社會責任,新冠檢測業務增量明顯。
報吿期內,預計非經常損益對淨利潤的影響金額範圍2000-2500萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.